

Title (en)
TUMOR ENVIRONMENT SPECIFIC EXPRESSION OF EFFECTOR GENES

Title (de)
TUMORUMGEBUNGSSPEZIFISCHE EXPRESSION VON EFFEKTORGENEN

Title (fr)
EXPRESSION SPECIFIQUE D'UN ENVIRONNEMENT TUMORAL DE GENES EFFECTEURS

Publication
EP 4031669 A4 20230104 (EN)

Application
EP 20866030 A 20200921

Priority
• US 201962903871 P 20190922
• US 201962949540 P 20191218
• IL 2020051026 W 20200921

Abstract (en)
[origin: WO2021053678A1] A Tumor Micro-Environment (TME) responsive expression vector including a nucleic acid sequence of a synthetic promoter, comprising two or more promoter- response-elements inducing expression of an immune-effector gene.

IPC 8 full level
C12N 15/63 (2006.01); **A61K 35/17** (2015.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C12N 15/85** (2006.01); **C12N 15/86** (2006.01)

CPC (source: EP IL US)
A61K 39/4611 (2023.05 - EP IL); **A61K 39/4613** (2023.05 - EP IL); **A61K 39/4631** (2023.05 - EP IL); **A61K 39/464406** (2023.05 - EP IL); **A61K 48/005** (2013.01 - IL); **A61K 48/0058** (2013.01 - IL); **A61P 35/00** (2018.01 - EP IL US); **C07K 14/7051** (2013.01 - US); **C12N 15/63** (2013.01 - EP IL); **C12N 15/85** (2013.01 - EP IL); **C12N 15/86** (2013.01 - US); **A61K 48/005** (2013.01 - EP); **A61K 48/0058** (2013.01 - EP); **C07K 2317/622** (2013.01 - US); **C07K 2319/03** (2013.01 - US); **C07K 2319/70** (2013.01 - US); **C12N 2830/002** (2013.01 - EP IL); **C12N 2830/008** (2013.01 - EP IL)

Citation (search report)
• [I] WO 2019159173 A1 20190822 - NAT INST BIOTECHNOLOGY NEGEV LTD [IL]
• [A] DOTTI G ET AL: "Design and development of therapies using chimeric antigen receptor-expressing T cells", IMMUNOL. REV., vol. 257, no. 1, 13 December 2013 (2013-12-13), pages 107 - 126, XP002791515, DOI: 10.1111/IMR.12131
• [A] JAVAN B & SHAHBAZI M ED - JAVAN B & SHAHBAZI M: "Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy", ECANCER., vol. 11, 6 July 2017 (2017-07-06), XP002791514, DOI: 10.3332/ECANCER.2017.751
• [A] D. L. VIALE ET AL: "Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 133, no. 11, 1 November 2013 (2013-11-01), pages 2576 - 2584, XP055719175, DOI: 10.1038/jid.2013.191
• [A] R. SAKEMURA ET AL: "A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. 8, 21 June 2016 (2016-06-21), US, pages 658 - 668, XP055513121, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-16-0043
• See also references of WO 2021053678A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2021053678 A1 20210325; AU 2020349708 A1 20220407; CN 114466932 A 20220510; EP 4031669 A1 20220727; EP 4031669 A4 20230104; IL 291357 A 20220501; US 2022315640 A1 20221006

DOCDB simple family (application)
IL 2020051026 W 20200921; AU 2020349708 A 20200921; CN 202080066878 A 20200921; EP 20866030 A 20200921; IL 29135722 A 20220314; US 202217699428 A 20220321